Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes
Sponsor
Solvay Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT00349128
Collaborator
(none)
382
51
7.5
Study Details
Study Description
Brief Summary
The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and dyslipidemia.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2/Phase 3 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia.
Study Start Date
:
Jan 1, 2004
Outcome Measures
Primary Outcome Measures
- Change in fasting triglycerides. []
Secondary Outcome Measures
- Assessment of lipid and glucose metabolisms. []
Eligibility Criteria
Criteria
Ages Eligible for Study:
20 Years
to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Type 2 diabetes mellitus
Exclusion Criteria:
- Type 1 diabetes, uncontrolled type 2 diabetes, - HbA1c ≥ 10 % - Fasting plasma glucose
300 mg/dL - Triglycerides > 500 mg/dL
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Site 201 | Katowice | Poland | ||
2 | Site 203 | Katowice | Poland | ||
3 | Site 202 | Warszawa | Poland | ||
4 | Site 204 | Zabrze | Poland | ||
5 | Site 111 | Dnipropetrovsk | Ukraine | ||
6 | Site 113 | Dnipropetrovsk | Ukraine | ||
7 | Site 108 | Kharkiv | Ukraine | ||
8 | Site 109 | Kharkiv | Ukraine | ||
9 | Site 101 | Kyiv | Ukraine | ||
10 | Site 102 | Kyiv | Ukraine | ||
11 | Site 103 | Kyiv | Ukraine | ||
12 | Site 104 | Kyiv | Ukraine | ||
13 | Site 105 | Kyiv | Ukraine | ||
14 | Site 106 | Kyiv | Ukraine | ||
15 | Site 107 | Kyiv | Ukraine | ||
16 | Site 112 | Zaporizhya | Ukraine | ||
17 | Site 35 | Acomb | United Kingdom | ||
18 | Site 21 | Atherstone | United Kingdom | ||
19 | Site 14 | Balsall Common | United Kingdom | ||
20 | Site 32 | Bangor | United Kingdom | ||
21 | Site 23 | Barry | United Kingdom | ||
22 | Site 36 | Basingstoke | United Kingdom | ||
23 | Site 8 | Bexhill-on-Sea | United Kingdom | ||
24 | Site 20 | Camberley | United Kingdom | ||
25 | Site 22 | Chesterfield | United Kingdom | ||
26 | Site 10 | Chippenham | United Kingdom | ||
27 | Site 13 | Coventry | United Kingdom | ||
28 | Site 31 | Doncaster | United Kingdom | ||
29 | Site 15 | Downpatrick | United Kingdom | ||
30 | Site 17 | Ely | United Kingdom | ||
31 | Site 4 | Ely | United Kingdom | ||
32 | Site 11 | Fife | United Kingdom | ||
33 | Site 1 | Frome | United Kingdom | ||
34 | Site 16 | Harrow | United Kingdom | ||
35 | Site 5 | Hastings | United Kingdom | ||
36 | Site 26 | Haverfordwest | United Kingdom | ||
37 | Site 19 | Keresley end | United Kingdom | ||
38 | Site 9 | Kingswood | United Kingdom | ||
39 | Site 25 | Newtownabbey | United Kingdom | ||
40 | Site 33 | Northampton | United Kingdom | ||
41 | Site 28 | Odiham | United Kingdom | ||
42 | Site 3 | Paignton | United Kingdom | ||
43 | Site 12 | Petersborough | United Kingdom | ||
44 | Site 7 | Randalstown | United Kingdom | ||
45 | Site 27 | Slough | United Kingdom | ||
46 | Site 6 | Soham | United Kingdom | ||
47 | Site 2 | South Glamorgan | United Kingdom | ||
48 | Site 34 | Stratford on Avon | United Kingdom | ||
49 | Site 29 | Swindon | United Kingdom | ||
50 | Site 30 | Trowbridge | United Kingdom | ||
51 | Site 18 | Yaxley | United Kingdom |
Sponsors and Collaborators
- Solvay Pharmaceuticals
Investigators
- Study Director: Global Clinical Director Solvay, Solvay Pharmaceuticals
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00349128
Other Study ID Numbers:
- C LF23-0121 03 01
First Posted:
Jul 6, 2006
Last Update Posted:
Sep 3, 2007
Last Verified:
Aug 1, 2007
Keywords provided by ,
,
Additional relevant MeSH terms: